UNSPSC 51372603: Ciramadol

This classification denotes an opioid receptor agonist with the molecular formula C15H23NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9NQ109OW0G, chemically known as phenol, 3-((r)-(dimethylamino)((1r,2r)-2-hydroxycyclohexyl)methyl)- but generally known as ciramadol, which bears US NIH Compound Identifier 44463. European Medicines Agency schedules Ciramadol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07477MIG.

UNSPSC 51372603 Ciramadol is a Commodity code representing a specific pharmaceutical product, yet recent state and local solicitations tagged with this code show minimal alignment with ciramadol procurement itself. Instead, the opportunities reflect broader pharmaceutical supply and pharmacy benefit management activities — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution. State and local governments are using this code (or broader pharmaceutical categories) to procure emergency opioid-reversal supplies, establish direct pharmacy contracting channels to reduce costs, and source generic drugs through cooperative purchasing agreements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (MMCAP, administered by the Minnesota Department of Administration). The work spans supply logistics, pharmacy benefit program design, and pharmaceutical manufacturer relationships rather than ciramadol-specific acquisitions.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's reach extending to participating states including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic pharmaceuticals and OTC products through three authorized wholesalers with awards effective July 1, 2026. The code shows limited recent activity specifically tied to ciramadol, suggesting either shallow procurement demand for this product at the state and local level or a tagging inconsistency between the UNSPSC classification and actual solicitation content.